Abstract
Prostate cancer (PCa) is the second most common cancer in men worldwide and the most frequently diagnosed cancer among men in more developed countries. The prognosis of PCa is excellent if detected at an early stage, making early screening crucial for detection and treatment. In recent years, a new form of diffusion magnetic resonance imaging called correlated diffusion imaging (CDI) was introduced, and preliminary results show promise as a screening tool for PCa. In the largest study of its kind, we investigate the relationship between PCa presence and a new variant of CDI we term synthetic correlated diffusion imaging (CDI$^s$), as well as its performance for PCa delineation compared to current standard MRI techniques (T2-weighted (T2w) imaging, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) imaging) across a cohort of 200 patient cases. Statistical analyses reveal that hyperintensity in CDI$^s$ is a strong indicator of PCa presence and achieves strong delineation of clinically significant cancerous tissue compared to T2w, DWI, and DCE. These results suggest that CDI$^s$ hyperintensity may be a powerful biomarker for the presence of PCa, and may have a clinical impact as a diagnostic aid for improving PCa screening.
Introduction
Prostate cancer (PCa) diagnosis remains a significant clinical challenge. While early detection is key to survival, current screening methods often lead to over-diagnosis and unnecessary invasive procedures for non-threatening tumors. Multi-Parametric MRI (MP-MRI) is the current gold standard, yet it faces limitations: T2-weighted (T2w) imaging often struggles to differentiate cancer from inflammation; Diffusion-Weighted Imaging (DWI) and its derivative, the Apparent Diffusion Coefficient (ADC), suffer from inter-scanner variability; and Dynamic Contrast-Enhanced (DCE) imaging requires contrast agents, increasing costs and patient risk.
Researchers from the University of Waterloo and the University of Toronto have introduced Synthetic Correlated Diffusion Imaging (CDI$^s$) to address these flaws. This technique aims to provide a consistent, high-contrast biomarker that clearly separates clinically significant cancer from healthy and insignificant tissue.
Methodology
CDI$^s$ builds upon Correlated Diffusion Imaging (CDI) by probing water molecule Brownian motion at multiple scales. The innovation lies in three key areas:
- Signal Synthesis: High-quality diffusion signals at high "q-values" are typically obscured by noise. The researchers utilized a signal synthesizer to create synthetic acquisitions from native data, uncovering diffusion characteristics usually hidden by noise.
- Calibrated Signal Mixing: A new mixing function analyzes joint correlations across multiple acquisitions. A calibration factor ($Z$) was introduced to ensure signal consistency across different MRI hardware and protocols, mitigating the "domain shift" problem common in medical imaging.
- Optimization: A tuned version (CDI$^s_t$) was developed using a Nelder-Mead Simplex strategy to maximize the area under the ROC curve (AUC).
Signal Separation and Contrast
A primary hurdle in standard MRI is the "gray zone" where signal distributions for healthy and cancerous tissue overlap. Histogram analysis reveals that CDI$^s$ hyperintensity creates a significantly cleaner separation between these classes.
As shown in the histograms, the signal distribution for PCa in CDI$^s$ is shifted significantly to the right compared to healthy tissue, with far less overlap than observed in ADC or T2w maps. This hyperintensity allows for much clearer identification of tumor boundaries.
Quantitative Performance
The study evaluated CDI$^s$ using a cohort of 200 patient cases from Radboud University Medical Centre, validated via histopathology. The quantitative results demonstrate that CDI$^s$ significantly outperforms existing clinical standards.
For the critical task of distinguishing PCa from healthy tissue, CDI$^s$ achieved an AUC of 0.9167, compared to 0.8859 for ADC and 0.7130 for T2w. Furthermore, CDI$^s$ proved highly effective at identifying "clinically significant" tissue (Gleason score $\ge$ 7), showing a marked reduction in overlap between significant and insignificant cancer compared to traditional ADC maps.
Conclusion
Synthetic Correlated Diffusion Imaging (CDI$^s$) represents a significant advancement in prostate cancer imaging. By synthesizing high-contrast signals and implementing a calibration framework for cross-scanner consistency, CDI$^s$ provides a more reliable biomarker for clinically significant PCa than current MP-MRI standards. Future work will focus on multi-center clinical validation and exploring the application of CDI$^s$ physics to other cancer types, such as breast and brain tumors.
Summary updated